Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World’s leading Event Organizer


14th Euro-Global Conference on Infectious Diseases

Berlin, Germany

Shyamapada Mandal

Shyamapada Mandal

University of Gour Banga, India

Title: Validation of anti-MPXV activity of myricetin by in silico methods


Biography: Shyamapada Mandal


The monkeypox, a localized zoonotic disease in Central and West Africa due to the monkeypox virus (MPXV) infection, is now a matter of global concern because of the (ongoing) multi-country outbreak in the rest of the world. An antiviral agent, Tecovirimat (TVM), designed to treat smallpox, is an FDA approved drug that is also licensed to treat monkeypox. However, due to the possible development of resistance to MPXV, TVM treatment failure of monkeypox might be anticipated. In order to check the antiviral efficacy of a plant-derived small molecule (myricetin; MRC) along with the standard drug TVM, against MPXV, molecular docking was performed between MPXV-based proteins (A42R profilin-like protein and MPXV-virulence protein) and the ligands (MRC and TVM), using AutoDock Vina. The binding energy (BE) of MRC to the A42R and virulence proteins were predicted as -7.8 and 7.0 kcal/mol, respectively, while the respective BE values for TVM were -9.0 and 7.6 kcal/mol. Furthermore, the acceptable ADMET profiles and Lipinski’s rule of five of MRC suggest the plant-based natural drug development with the studied compound for combating the monkeypox.